Is heart rate variability a valuable method to investigate cardiac autonomic dysfunction in subjects with leukemia? A systematic review to evaluate its importance in clinical practice

Autor(es)

Kirizawa, Jociele M. ^[1] ; Garner, David M. ^[2] ; Arab, Claudia ^[3] ; Valenti, Vitor E. ^{[1, 4]}

Afiliação do(s) autor(es)

^[1] Sao Paulo State Univ, UNESP, Auton Nervous Syst Ctr, Presidente Prudente, SP - Brazil

^[2] Oxford Brookes Univ, Fac Hlth & Life Sci, Dept Biol & Med Sci, Cardioresp Res Grp, Headington Campus, Gipsy Lane, Oxford OX3 0BP - England

^[3] Fed Univ Sao Paulo UNIFESP, Dept Med Cardiol, Sao Paulo, SP - Brazil

^[4] UNESP, Av Hygino Muzzi Filho 737, BR-17 52590 Marilia, SP - Brazil

• Tipo de documento: Artigo de Revisão
• Fonte: SUPPORTIVE CARE IN CANCER; v. 28, n. 1, p. 35-42, JAN 2020.
• Citações Web of Science: 2

Resumo

Impaired cardiovascular and autonomic function during treatment and during recovery from leukemia has been indicated. In this context, heart rate variability (HRV) is a non-invasive measure that describes the oscillations of the intervals between consecutive heart beats (RR intervals), influenced by the autonomic nervous system. We intend to review literature showing HRV changes in leukemia subjects. The articles selected in the current review were attained up to March 2018, and the search was limited to articles in English language, published in peer-reviewed journals, with both adult and child age samples. The articles were investigated in the five electronic databases: PubMed, Physiotherapy Evidence Database (PEDro), Cochrane Clinical Trials, Scientific Electronic Library Online (SciELO), and Excerpta Medica dataBASE (EMBASE). Towards the end of the research, 9 studies were included. Subjects undergoing treatment for leukemia have reduced HRV, signifying decreased vagal control of heart rate. The subjects that undertook leukemia treatment and their survivors experienced a reduction in HRV with subsequent recovery, but the recovery time is ill defined. HRV is reduced in leukemia subjects who progress to neuropathy secondary to chemotherapy, accompanied by cardiac dysfunction. We advocate the use of HRV to evaluate autonomic function and decide the treatment to prevent autonomic impairment in leukemia subjects. (AU)

• Processo FAPESP: 18/19134-0 - Razão cálculo-stature e sua relação com a recuperação autônoma do exercício aeróbio em homens saudáveis
• Beneficiário: Vitor Engrácia Valenti
• Modalidade de apoio: Auxílio à Pesquisa - Publicações científicas - Artigo